AUB ScholarWorks

Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed-refractory adult T-cell leukemia-lymphoma

Show simple item record

dc.contributor.author Hermine O.
dc.contributor.author Dombret H.
dc.contributor.author Poupon J.
dc.contributor.author Arnulf B.
dc.contributor.author Lefrere F.
dc.contributor.author Rousselot P.
dc.contributor.author Damaj G.
dc.contributor.author Delarue R.
dc.contributor.author Fermand J.P.
dc.contributor.author Brouet J.C.
dc.contributor.author Degos L.
dc.contributor.author Varet B.
dc.contributor.author de The H.
dc.contributor.author Bazarbachi A.
dc.contributor.editor
dc.date May-2004
dc.date.accessioned 2017-10-05T15:37:36Z
dc.date.available 2017-10-05T15:37:36Z
dc.date.issued 2004
dc.identifier 10.1038/sj.thj.6200374
dc.identifier.isbn
dc.identifier.issn 14664860
dc.identifier.uri http://hdl.handle.net/10938/15817
dc.description.abstract Human T-cell lymphotropic virus type 1 associated adult T-cell leukemia-lymphoma carries a very poor prognosis due to its intrinsic resistance to chemotherapy. Although zidovudine (AZT) and α -interferon (IFN) yield some responses and improve ATL prognosis, alternative therapies are needed. Arsenic trioxide (As) dramatically synergizes with IFN to induce growth arrest and apoptosis of ATL leukemia cells in vitro. These results prompted us to initiate a phase II trial of As-IFN combination in seven patients with relapsed-refractory ATL (four acute and three lymphoma). Four patients exhibited a clear initial response (one complete remission and three partial remissions). Yet, the treatment was discontinued after a median of 22 days because of toxicity (three patients) or subsequent progression (four patients). Six patients eventually died from progressive disease (five patients) or infection (one patient), but the remaining patient is still alive and disease free at 32 months. Pharmacokinetic studies showed that maximum arsenic blood levels (median 0.46μM) were slowly achieved (8-15 days). In conclusion, arsenic-IFN treatment is feasible and exhibits an anti-leukemia effect in very poor prognosis ATL patients despite a significant toxicity. Future studies should assess the best timing for arsenic therapy: frontline with IFN-AZT or as maintenance after induction. © 2004 The European Hematology Association. All rights reserved.
dc.format.extent
dc.format.extent Pages: (130-134)
dc.language English
dc.publisher LONDON
dc.relation.ispartof Publication Name: Hematology Journal; Publication Year: 2004; Volume: 5; no. 2; Pages: (130-134);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed-refractory adult T-cell leukemia-lymphoma
dc.type Article
dc.contributor.affiliation Hermine, O., Department of Hematology, Necker Hospital, 149-161 rue de Sevres, 75743 Paris Cedex 15, France, CNRS UMR 8603, Necker Hospital, 149-161 rue de Sevres, 75743 Paris Cedex 15, France
dc.contributor.affiliation Dombret, H., Department of Hematology, Saint-Louis Hospital, Paris, France
dc.contributor.affiliation Poupon, J., Department of Pharmacology, Lariboisière Hospital, Paris, France
dc.contributor.affiliation Arnulf, B., Department of Hematology, Necker Hospital, 149-161 rue de Sevres, 75743 Paris Cedex 15, France, CNRS UMR 8603, Necker Hospital, 149-161 rue de Sevres, 75743 Paris Cedex 15, France
dc.contributor.affiliation Lefrère, F., Department of Hematology, Necker Hospital, 149-161 rue de Sevres, 75743 Paris Cedex 15, France
dc.contributor.affiliation Rousselot, P., Department of Hematology, Saint-Louis Hospital, Paris, France
dc.contributor.affiliation Damaj, G., Department of Hematology, Necker Hospital, 149-161 rue de Sevres, 75743 Paris Cedex 15, France
dc.contributor.affiliation Delarue, R., Department of Hematology, Necker Hospital, 149-161 rue de Sevres, 75743 Paris Cedex 15, France
dc.contributor.affiliation Fermand, J.P., Department of Immuno-Hematology, Saint-Louis Hospital, Paris, France
dc.contributor.affiliation Brouet, J.C., Department of Immuno-Hematology, Saint-Louis Hospital, Paris, France
dc.contributor.affiliation Degos, L., Department of Hematology, Saint-Louis Hospital, Paris, France
dc.contributor.affiliation Varet, B., Department of Hematology, Necker Hospital, 149-161 rue de Sevres, 75743 Paris Cedex 15, France, CNRS UMR 8603, Necker Hospital, 149-161 rue de Sevres, 75743 Paris Cedex 15, France
dc.contributor.affiliation de Thé, H., CNRS UPR 9051, Saint-Louis Hospital, Paris, France
dc.contributor.affiliation Bazarbachi, A., Department of Internal Medicine, American University of Beirut, PO Box 113-6044, Beirut, Lebanon
dc.contributor.authorAddress Hermine, O.; Department of Hematology, Hôpital Necker, 149-161 rue de Sevres, 75743 Paris Cedex 15, France; email: hermine@necker.fr
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.authorDivision
dc.contributor.authorEmail hermine@necker.fr; bazarbac@aub.edu.lb
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Hermine, O
dc.contributor.authorInitials Dombret, H
dc.contributor.authorInitials Poupon, J
dc.contributor.authorInitials Arnulf, B
dc.contributor.authorInitials Lefrere, F
dc.contributor.authorInitials Rousselot, P
dc.contributor.authorInitials Damaj, G
dc.contributor.authorInitials Delarue, R
dc.contributor.authorInitials Fermand, JP
dc.contributor.authorInitials Brouet, JC
dc.contributor.authorInitials Degos, L
dc.contributor.authorInitials Varet, B
dc.contributor.authorInitials de The, H
dc.contributor.authorInitials Bazarbachi, A
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Hermine, O (reprint author), Hop Necker Enfants Malad, Dept Hematol, 149-161 Rue Sevres, F-75743 Paris 15, France.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Bazarbachi A, 2001, VIRUS RES, V78, P79, DOI 10.1016-S0168-1702(01)00286-6; BAZARBACHI A, 1999, BLOOD, V93, P279; Bazarbachi A, 1996, J ACQ IMMUN DEF SYND, V13, pS186, DOI 10.1097-00042560-199600001-00028; Chen GQ, 1996, BLOOD, V88, P1052; El-Sabban ME, 2000, BLOOD, V96, P2849; GILL PS, 1995, NEW ENGL J MED, V332, P1744, DOI 10.1056-NEJM199506293322603; Hanon E, 2000, BLOOD, V95, P1386; HERMINE O, 1995, NEW ENGL J MED, V332, P1749, DOI 10.1056-NEJM199506293322604; Hermine Olivier, 2002, Hematol J, V3, P276, DOI 10.1038-sj.thj.6200195; Hermine O, 1998, BIODRUGS, V10, P447, DOI 10.2165-00063030-199810060-00003; HINUMA Y, 1982, INT J CANCER, V29, P631, DOI 10.1002-ijc.2910290606; Nasr R, 2003, BLOOD, V101, P4576, DOI 10.1182-blood-2002-09-2986; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111-j.1365-2141.1991.tb08051.x; Shimoyama M., 1992, ADV ADULT T CELL LEU, P43; Taguchi Hirokuni, 1994, Blood, V84, p479A; Zhu J, 2001, ONCOGENE, V20, P7257, DOI 10.1038-sj.onc.1204852
dc.description.citedCount 72
dc.description.citedTotWOSCount 72
dc.description.citedWOSCount 67
dc.format.extentCount 5
dc.identifier.articleNo
dc.identifier.coden HJEOB
dc.identifier.pubmedID 15048063
dc.identifier.scopusID 11144356179
dc.identifier.url
dc.publisher.address MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr Hematol. J.
dc.relation.ispartOfIssue 2
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle Hematology Journal
dc.relation.ispartofPubTitleAbbr Hematol. J.
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 5
dc.source.ID WOS:000227358200006
dc.type.publication Journal
dc.subject.otherAuthKeyword Arsenic
dc.subject.otherAuthKeyword HTLV-I. ATL
dc.subject.otherAuthKeyword Interferon
dc.subject.otherAuthKeyword Leukemia
dc.subject.otherAuthKeyword Lymphoma
dc.subject.otherChemCAS arsenic trioxide, 1303-24-8, 1327-53-3, 13464-58-9, 15502-74-6
dc.subject.otherChemCAS cotrimoxazole, 8064-90-2
dc.subject.otherChemCAS lamivudine, 134678-17-4, 134680-32-3
dc.subject.otherChemCAS tiabendazole, 148-79-8
dc.subject.otherChemCAS zidovudine, 30516-87-1
dc.subject.otherChemCAS Anti-HIV Agents
dc.subject.otherChemCAS Antineoplastic Agents
dc.subject.otherChemCAS arsenic trioxide, 1327-53-3
dc.subject.otherChemCAS Arsenicals
dc.subject.otherChemCAS Interferon-alpha
dc.subject.otherChemCAS Oxides
dc.subject.otherChemCAS Zidovudine, 30516-87-1
dc.subject.otherIndex arsenic trioxide
dc.subject.otherIndex cotrimoxazole
dc.subject.otherIndex lamivudine
dc.subject.otherIndex recombinant alpha2a interferon
dc.subject.otherIndex tiabendazole
dc.subject.otherIndex zidovudine
dc.subject.otherIndex abdominal cramp
dc.subject.otherIndex adult
dc.subject.otherIndex anemia
dc.subject.otherIndex antineoplastic activity
dc.subject.otherIndex article
dc.subject.otherIndex blood toxicity
dc.subject.otherIndex cancer growth
dc.subject.otherIndex cancer recurrence
dc.subject.otherIndex cancer survival
dc.subject.otherIndex cardiotoxicity
dc.subject.otherIndex chemotherapy induced emesis
dc.subject.otherIndex cholestasis
dc.subject.otherIndex clinical article
dc.subject.otherIndex clinical trial
dc.subject.otherIndex confusion
dc.subject.otherIndex controlled clinical trial
dc.subject.otherIndex controlled study
dc.subject.otherIndex cytolysis
dc.subject.otherIndex diarrhea
dc.subject.otherIndex dose time effect relation
dc.subject.otherIndex drug activation
dc.subject.otherIndex drug blood level
dc.subject.otherIndex drug dose regimen
dc.subject.otherIndex drug efficacy
dc.subject.otherIndex drug fatality
dc.subject.otherIndex drug potentiation
dc.subject.otherIndex drug withdrawal
dc.subject.otherIndex facial nerve paralysis
dc.subject.otherIndex female
dc.subject.otherIndex gastrointestinal toxicity
dc.subject.otherIndex heart arrhythmia
dc.subject.otherIndex human
dc.subject.otherIndex Human T cell leukemia virus 1
dc.subject.otherIndex leukemia remission
dc.subject.otherIndex liver toxicity
dc.subject.otherIndex lung infection
dc.subject.otherIndex male
dc.subject.otherIndex mental disease
dc.subject.otherIndex neurotoxicity
dc.subject.otherIndex neutropenia
dc.subject.otherIndex paresthesia
dc.subject.otherIndex phase 2 clinical trial
dc.subject.otherIndex Pneumocystis pneumonia
dc.subject.otherIndex QT prolongation
dc.subject.otherIndex side effect
dc.subject.otherIndex skin toxicity
dc.subject.otherIndex strongyloidiasis
dc.subject.otherIndex T cell leukemia
dc.subject.otherIndex T cell lymphoma
dc.subject.otherIndex tachycardia
dc.subject.otherIndex thrombocytopenia
dc.subject.otherIndex Adult
dc.subject.otherIndex Anti-HIV Agents
dc.subject.otherIndex Antineoplastic Agents
dc.subject.otherIndex Arsenicals
dc.subject.otherIndex Female
dc.subject.otherIndex Human T-lymphotropic virus 1
dc.subject.otherIndex Humans
dc.subject.otherIndex Injections, Intravenous
dc.subject.otherIndex Interferon-alpha
dc.subject.otherIndex Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated
dc.subject.otherIndex Middle Aged
dc.subject.otherIndex Oxides
dc.subject.otherIndex Prognosis
dc.subject.otherIndex Recurrence
dc.subject.otherIndex Treatment Outcome
dc.subject.otherIndex Zidovudine
dc.subject.otherKeywordPlus LEUKEMIA-LYMPHOMA
dc.subject.otherKeywordPlus DOWN-REGULATION
dc.subject.otherKeywordPlus HTLV-I
dc.subject.otherKeywordPlus ZIDOVUDINE
dc.subject.otherKeywordPlus COMBINATION
dc.subject.otherKeywordPlus EXPRESSION
dc.subject.otherKeywordPlus APOPTOSIS
dc.subject.otherKeywordPlus ALFA
dc.subject.otherWOS Hematology


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account